JGJan Grosser

Jan Grosser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Grosser has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Topoisomerase regulation in the interplay between DNA transcription and replication

    by Jan Grosser

    During DNA-involving processes such as transcription and replication the double helix is subjected to torsional stress. The over- or under-winding that encompasses torsional stress can be resolved by enzymes called topoisomerases. These enzymes cleave either one (Topoisomerase 1) or both (Topoisomerase 2) of the DNA strands, which allows for DNA relaxation, before resealing the break. Topoisomerase activity can be regulated by transcription or replication factors to fine-tune the efficiency of the genomic processes in which they are involved. Because cancers cells heavily rely on topoisomerases, these enzymes are common targets in cancer treatment.In this thesis, I have investigated topoisomerase regulation during transcription and replication, as well as new pharmacological strategies targeting the regulation of topoisomerase activity. The long-term goal of this thesis project is to develop approaches to selectively affect cancer cells viability. In paper 1, we focused on studying how the RNA polymerase 2 modulates Topoisomerase 1 during mitotic transcription. In paper 2, we investigated the mechanism of cellular adaptation to Topoisomerase 1 inhibitors. In paper 3, we developed a therapeutic approach that blocks the interaction between RNA polymerase 2 and Topoisomerase 1. We tested the strategy in preclinical models of pancreatic cancers. We showed that the treatment is effective and specific for the cancer cells and we have characterized the mechanism of cell killing.The thesis work integrates genomics, molecular biology, and drug screen methodologies, as well as preclinical mouse work done in collaboration. This works identifies Topoisomerase 1 as an important player in ensuring correct recruitment of various factors needed for transcription elongation, splicing and termination. The findings increase our understanding of regulatory pathways controlled by Topoisomerase 1 to protect DNA integrity and provide the rationale for the development of new approaches that target Topoisomerase 1 for cancer treatment.List of scientific papersI. "Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1" - Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radoslaw Grochowski, Ivana Karabogdan, Nicola Crosetto, Arne Lindqvist, Anna Helene Bizard, Fedor Kouzine, Toyoaki Natsume, and Laura Baranello; Molecular Cell 81, 5007-5024.https://doi.org/10.1016/j.molcel.2021.10.015II. "NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors" - Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni; Sci. Adv. 8, eabq0648 (2022).https://doi.org/10.1126/sciadv.abq0648III. "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" - Donald P. Cameron*, Jan Grosser*, Swetlana Ladigan*, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, Phyllis F. Cheung, Deepak Vangala, Michael Pohl, Richard Viebahn, Christian Teschendorf, Heiner Wolters, Selami Usta, Keyi Geng, Claudia Kutter, Marie Arsenian-Henriksson, Jens T. Siveke, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Laura Baranello; Sci. Adv. 9, eadg5109 (2023).https://doi.org/10.1126/sciadv.adg5109

  • Open Access

    Topoisomerase regulation in the interplay between DNA transcription and replication

    by Jan Grosser

    During DNA-involving processes such as transcription and replication the double helix is subjected to torsional stress. The over- or under-winding that encompasses torsional stress can be resolved by enzymes called topoisomerases. These enzymes cleave either one (Topoisomerase 1) or both (Topoisomerase 2) of the DNA strands, which allows for DNA relaxation, before resealing the break. Topoisomerase activity can be regulated by transcription or replication factors to fine-tune the efficiency of the genomic processes in which they are involved. Because cancers cells heavily rely on topoisomerases, these enzymes are common targets in cancer treatment.In this thesis, I have investigated topoisomerase regulation during transcription and replication, as well as new pharmacological strategies targeting the regulation of topoisomerase activity. The long-term goal of this thesis project is to develop approaches to selectively affect cancer cells viability. In paper 1, we focused on studying how the RNA polymerase 2 modulates Topoisomerase 1 during mitotic transcription. In paper 2, we investigated the mechanism of cellular adaptation to Topoisomerase 1 inhibitors. In paper 3, we developed a therapeutic approach that blocks the interaction between RNA polymerase 2 and Topoisomerase 1. We tested the strategy in preclinical models of pancreatic cancers. We showed that the treatment is effective and specific for the cancer cells and we have characterized the mechanism of cell killing.The thesis work integrates genomics, molecular biology, and drug screen methodologies, as well as preclinical mouse work done in collaboration. This works identifies Topoisomerase 1 as an important player in ensuring correct recruitment of various factors needed for transcription elongation, splicing and termination. The findings increase our understanding of regulatory pathways controlled by Topoisomerase 1 to protect DNA integrity and provide the rationale for the development of new approaches that target Topoisomerase 1 for cancer treatment.List of scientific papersI. "Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1" - Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radoslaw Grochowski, Ivana Karabogdan, Nicola Crosetto, Arne Lindqvist, Anna Helene Bizard, Fedor Kouzine, Toyoaki Natsume, and Laura Baranello; Molecular Cell 81, 5007-5024.https://doi.org/10.1016/j.molcel.2021.10.015II. "NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors" - Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni; Sci. Adv. 8, eabq0648 (2022).https://doi.org/10.1126/sciadv.abq0648III. "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" - Donald P. Cameron*, Jan Grosser*, Swetlana Ladigan*, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, Phyllis F. Cheung, Deepak Vangala, Michael Pohl, Richard Viebahn, Christian Teschendorf, Heiner Wolters, Selami Usta, Keyi Geng, Claudia Kutter, Marie Arsenian-Henriksson, Jens T. Siveke, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Laura Baranello; Sci. Adv. 9, eadg5109 (2023).https://doi.org/10.1126/sciadv.adg5109

  • Open Access

    Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

    by Donald P. Cameron, Jan Grosser, Swetlana Ladigan, Vladislav Kuzin, Evanthia Iliopoulou, Anika Wiegard, Hajar Benredjem, Kathryn Jackson, Sven T. Liffers, Smiths Lueong, et al.

    Pancreatic carcinoma lacks effective therapeutic strategies resulting in poor prognosis. Transcriptional dysregulation due to alterations in KRAS and MYC affects initiation, development, and survival of this tumor type. Using patient-derived xenografts of KRAS- and MYC-driven pancreatic carcinoma, we show that coinhibition of topoisomerase 1 (TOP1) and bromodomain-containing protein 4 (BRD4) synergistically induces tumor regression by targeting promoter pause release. Comparing the nascent transcriptome with the recruitment of elongation and termination factors, we found that coinhibition of TOP1 and BRD4 disrupts recruitment of transcription termination factors. Thus, RNA polymerases transcribe downstream of genes for hundreds of kilobases leading to readthrough transcription. This occurs during replication, perturbing replisome progression and inducing DNA damage. The synergistic effect of TOP1 + BRD4 inhibition is specific to cancer cells leaving normal cells unaffected, highlighting the tumor’s vulnerability to transcriptional defects. This preclinical study provides a mechanistic understanding of the benefit of combining TOP1 and BRD4 inhibitors to treat pancreatic carcinomas addicted to oncogenic drivers of transcription and replication.


  • Publisher Correction: Nascent Ribo-Seq measures ribosomal loading time and reveals kinetic impact on ribosome density

    by Johanna Schott, Sonja Reitter, Doris Lindner, Jan Grosser, Marius Bruer, Anjana Shenoy, Tamar Geiger, Arthur Mathes, Gergana Dobreva, Georg Stoecklin


  • Open Access

    NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors

    by Alice Meroni, Jan Grosser, Sumedha Agashe, Natasha Ramakrishnan, Jessica Jackson, Priyanka Verma, Laura Baranello, Alessandro Vindigni

    DNA topoisomerase 1 (TOP1) inhibitors are mainstays of anticancer therapy. These drugs trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of TOP1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of TOP1, we show that cells adapt to treatment with multiple doses of TOP1 inhibitor by promoting the degradation of TOP1-ccs, allowing cells to better tolerate subsequent doses of TOP1 inhibitor. The E3-RING Cullin 3 ligase in complex with the BTBD1 and BTBD2 adaptor proteins promotes TOP1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway, and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to TOP1 inhibitors. Collectively, our data uncover a previously unidentified NEDD8–Cullin 3 pathway involved in the adaptive response to TOP1 inhibitors, which can be targeted to improve the efficacy of TOP1 drugs in cancer therapy.


  • Open Access

    Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1

    by Anika Wiegard, Vladislav Kuzin, Donald P. Cameron, Jan Grosser, Michele Ceribelli, Rashid Mehmood, Roberto Ballarino, Francesco Valant, Radosław Grochowski, Ivana Karabogdan, et al.


  • Open Access

    Deficiency of Polη in Saccharomyces cerevisiae reveals the impact of transcription on damage-induced cohesion

    by Pei-Shang Wu, Jan Grosser, Donald P. Cameron, Laura Baranello, Lena Ström

    The structural maintenance of chromosome (SMC) complex cohesin mediates sister chromatid cohesion established during replication, and damage-induced cohesion formed in response to DSBs post-replication. The translesion synthesis polymerase Polη is required for damage-induced cohesion through a hitherto unknown mechanism. Since Polη is functionally associated with transcription, and transcription triggers de novo cohesion in Schizosaccharomyces pombe, we hypothesized that transcription facilitates damage-induced cohesion in Saccharomyces cerevisiae. Here, we show dysregulated transcriptional profiles in the Polη null mutant (rad30Δ), where genes involved in chromatin assembly and positive transcription regulation were downregulated. In addition, chromatin association of RNA polymerase II was reduced at promoters and coding regions in rad30Δ compared to WT cells, while occupancy of the H2A.Z variant (Htz1) at promoters was increased in rad30Δ cells. Perturbing histone exchange at promoters inactivated damage-induced cohesion, similarly to deletion of the RAD30 gene. Conversely, altering regulation of transcription elongation suppressed the deficient damage-induced cohesion in rad30Δ cells. Furthermore, transcription inhibition negatively affected formation of damage-induced cohesion. These results indicate that the transcriptional deregulation of the Polη null mutant is connected with its reduced capacity to establish damage-induced cohesion. This also suggests a linkage between regulation of transcription and formation of damage-induced cohesion after replication.


  • Nascent Ribo-Seq measures ribosomal loading time and reveals kinetic impact on ribosome density

    by Johanna Schott, Sonja Reitter, Doris Lindner, Jan Grosser, Marius Bruer, Anjana Shenoy, Tamar Geiger, Arthur Mathes, Gergana Dobreva, Georg Stoecklin

    In general, mRNAs are assumed to be loaded with ribosomes instantly upon entry into the cytoplasm. To measure ribosome density (RD) on nascent mRNA, we developed nascent Ribo-Seq by combining Ribo-Seq with progressive 4-thiouridine labeling. In mouse macrophages, we determined experimentally the lag between the appearance of nascent mRNA and its association with ribosomes, which was calculated to be 20–22 min for bulk mRNA. In mouse embryonic stem cells, nRibo-Seq revealed an even stronger lag of 35–38 min in ribosome loading. After stimulation of macrophages with lipopolysaccharide, the lag between cytoplasmic and translated mRNA leads to uncoupling between input and ribosome-protected fragments, which gives rise to distorted RD measurements under conditions where mRNA amounts are far from steady-state expression. As a result, we demonstrate that transcriptional changes affect RD in a passive way.